1-12 of 12
Elizabeth R. Plimack
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

H. Josh Jang, Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. Quinn, Jean-Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2052–2065.
https://doi.org/10.1158/1078-0432.CCR-22-3642
Published: 01 June 2023
View articletitled, A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Open the PDF for A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy in another window
Includes: Supplementary data
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View articletitled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View articletitled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

Judit Börcsök, Zsofia Sztupinszki, Raie Bekele, Sizhi P. Gao, Miklos Diossy, Amruta S. Samant, Kasia M. Dillon, Viktoria Tisza, Sándor Spisák, Orsolya Rusz, Istvan Csabai, Helle Pappot, Zoë J. Frazier, David J. Konieczkowski, David Liu, Naresh Vasani, James A. Rodrigues, David B. Solit, Jean H. Hoffman-Censits, Elizabeth R. Plimack, Jonathan E. Rosenberg, Jean-Bernard Lazaro, Mary-Ellen Taplin, Gopa Iyer, Søren Brunak, Rita Lozsa, Eliezer M. Van Allen, Dávid Szüts, Kent W. Mouw, Zoltan Szallasi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 2011–2022.
https://doi.org/10.1158/1078-0432.CCR-20-3316
Published: 01 April 2021
View articletitled, Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
Open the PDF for Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer in another window
Includes: Supplementary data
Journal Articles

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer N. Fishman, Daniel C. Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C. Fernandez, Jamal C. Tarazi, Saby George, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5598–5608.
https://doi.org/10.1158/1078-0432.CCR-20-1408
Published: 02 November 2020
View articletitled, Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Open the PDF for Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B29: Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy

Phillip H. Abbosh, Uttam Satyal, David Liu, Ilsiya Ibragimova, Lauren Szeto, Benjamin Miron, James Ford, Daniel Parker, Aeen Asgar, Daniel M. Geynisman, R. Katherine Alpaugh, Paul Cairns, Costas D. Lallas, Edouard J. Trabulsi, Jean Hoffman-Censits, Eliezer M. Van Allen, Alexander Kutikov, Elizabeth R. Plimack
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): B29.
https://doi.org/10.1158/1557-3265.BLADDER19-B29
Published: 03 August 2020
View articletitled, Abstract B29: Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy
Journal Articles

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Qiang Li, Alexis W. Damish, Zoë Frazier, David Liu, Elizaveta Reznichenko, Atanas Kamburov, Andrew Bell, Huiyong Zhao, Emmet J. Jordan, S. Paul Gao, Jennifer Ma, Philip H. Abbosh, Joaquim Bellmunt, Elizabeth R. Plimack, Jean-Bernard Lazaro, David B. Solit, Dean Bajorin, Jonathan E. Rosenberg, Alan D. D'Andrea, Nadeem Riaz, Eliezer M. Van Allen, Gopa Iyer, Kent W. Mouw
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 977–988.
https://doi.org/10.1158/1078-0432.CCR-18-1001
Published: 01 February 2019
View articletitled, ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Open the PDF for ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, Musa Mutyaba, Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3557–3565.
https://doi.org/10.1158/1078-0432.CCR-16-2395
Published: 13 July 2017
View articletitled, The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Open the PDF for The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

Noah M. Hahn, Trinity J. Bivalacqua, Ashley E. Ross, George J. Netto, Alex Baras, Jong Chul Park, Carolyn Chapman, Timothy A. Masterson, Michael O. Koch, Richard Bihrle, Richard S. Foster, Thomas A. Gardner, Liang Cheng, David R. Jones, Kyle McElyea, George E. Sandusky, Timothy Breen, Ziyue Liu, Costantine Albany, Marietta L. Moore, Rhoda L. Loman, Angela Reed, Scott A. Turner, Francine B. De Abreu, Torrey Gallagher, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, Daniel M. Geynisman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3003–3011.
https://doi.org/10.1158/1078-0432.CCR-16-2267
Published: 14 June 2017
View articletitled, A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Open the PDF for A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157 in another window
Includes: Supplementary data
Journal Articles

Abstract B14: Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy

Philip H. Abbosh, David Liu, Michael H. Johnson, Wafik S. El-Deiry, Elizabeth R. Plimack, Jonathan E. Rosenberg, Eliezer M. Van Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1_Supplement): B14.
https://doi.org/10.1158/1557-3265.PMCCAVULN16-B14
Published: 02 January 2017
View articletitled, Abstract B14: Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy
Journal Articles

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5461–5471.
https://doi.org/10.1158/1078-0432.CCR-15-2839
Published: 14 November 2016
View articletitled, Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Open the PDF for Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

Paul Haluska, Michael Menefee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, Patricia LoRusso
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (18): 4747–4757.
https://doi.org/10.1158/1078-0432.CCR-14-0114
Published: 14 September 2014
View articletitled, Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data